KeyCorp Boosts Repligen (NASDAQ:RGEN) Price Target to $220.0

Repligen (NASDAQ:RGEN – Free Report) had its target price lifted by KeyCorp from $210.00 to $220.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock. RGEN has been the subject of several other research reports. JPMorgan Chase & Co. upped their price target on […]

Related Keywords

United States , Canada , America , Asia Pacific , Stifel Nicolaus , Fortis Capital Advisors , Jpmorgan Chase Co , Mitsubishi Ufj , Asset Management Co , Repligen Corporation , Commerce Bank , Royal Bank , Keycorp , Free Report , Moderate Buy , Capital Advisors , Get Free Report , North America , Repligen Daily , Repligen , Nasdaq Rgen , Rgen , Medical , 75991610 , Boost Price Target ,